Kollicoat® Smartseal 100P for Developing Theophylline Pellets: Exploring Taste-Masking Potential for Pediatric Applications

<b>Background/Objectives:</b> This study aimed to develop and evaluate taste-masked theophylline pellets using hot-melt extrusion (HME) technology. Additionally, the study evaluates the efficacy of various taste-masking polymers by comparing three pH-dependent polymers, Kollicoat<sup>®</sup> Smartseal 100P, Eudragit<sup>®</sup> EPO, and Kollicoat<sup>®</sup> MAE 100-55, in masking taste and optimizing drug release. <b>Methods:</b> Formulations were designed with varying drug loads (10%, 20%, and 30%) and plasticizer concentrations (20% and 30% PEG 1500). Lead formulations were characterized using differential scanning calorimetry (DSC), Fourier transform infrared spectroscopy (FTIR), bitter threshold level, and in vitro release testing. Stability was assessed under accelerated conditions (40 °C ± 2 °C and 75% ± 5% RH) for three months. <b>Results:</b> DSC confirmed homogenous dispersion of the drug within the polymer matrix. The optimized formulation comprising 20% theophylline, 20% PEG 1500, and 60% Kollicoat<sup>®</sup> Smartseal 100P demonstrated effective taste masking, releasing only 1.1% of the drug in simulated salivary fluid (SSF) within two minutes, significantly lower than the pure drug (29.5%, <i>p</i> < 0.05), Kollicoat<sup>®</sup> MAE 100-55 (2.8%, <i>p</i> < 0.05), and comparable to Eudragit<sup>®</sup> EPO (2.1%, <i>p</i> > 0.05). Solubility studies further confirmed that theophylline release from the lead formulations remained well below its reported bitter threshold, which could prevent taste perception and mitigate bitterness. In gastric fluid, complete drug release was achieved from Kollicoat<sup>®</sup> Smartseal 100P and Eudragit<sup>®</sup> EPO, while Kollicoat<sup>®</sup> MAE 100-55 exhibited limited release. Stability studies showed that the Kollicoat<sup>®</sup> Smartseal 100P formulation maintained its texture, taste-masking efficacy, and dissolution profile under accelerated conditions. <b>Conclusions:</b> The study demonstrates the novel exploration of Kollicoat<sup>®</sup> Smartseal 100P for HME application, and its effectiveness in achieving robust taste masking for theophylline, improving patient compliance, particularly in pediatric and geriatric populations.

Authors

Institutions

Publication Details

Journal
Pharmaceutics
Published
2025-03-25
DOI
https://doi.org/10.3390/pharmaceutics17040413
Citations
3
Primary Topic
Advanced Drug Delivery Systems
Type
article
Field-Weighted Citation Impact
2.37
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Kollicoat® Smartseal 100P for Developing Theophylline Pellets: Exploring Taste-Masking Potential for Pediatric Applications

Neeraja Komanduri, Rasha M. Elkanayati, Michael A. Repka, Nagireddy Dumpa et al.
3 citations
Pharmaceutics
Advanced Drug Delivery Systems
2.37
article

Kollicoat® Smartseal 100P for Developing Theophylline Pellets: Exploring Taste-Masking Potential for Pediatric Applications

Neeraja Komanduri, Rasha M. Elkanayati, Michael A. Repka, Nagireddy Dumpa, Mashan Almutairi, Arun Butreddy, Suresh Bandari
article en
3 citations

Abstract

<b>Background/Objectives:</b> This study aimed to develop and evaluate taste-masked theophylline pellets using hot-melt extrusion (HME) technology. Additionally, the study evaluates the efficacy of various taste-masking polymers by comparing three pH-dependent polymers, Kollicoat<sup>®</sup> Smartseal 100P, Eudragit<sup>®</sup> EPO, and Kollicoat<sup>®</sup> MAE 100-55, in masking taste and optimizing drug release. <b>Methods:</b> Formulations were designed with varying drug loads (10%, 20%, and 30%) and plasticizer concentrations (20% and 30% PEG 1500). Lead formulations were characterized using differential scanning calorimetry (DSC), Fourier transform infrared spectroscopy (FTIR), bitter threshold level, and in vitro release testing. Stability was assessed under accelerated conditions (40 °C ± 2 °C and 75% ± 5% RH) for three months. <b>Results:</b> DSC confirmed homogenous dispersion of the drug within the polymer matrix. The optimized formulation comprising 20% theophylline, 20% PEG 1500, and 60% Kollicoat<sup>®</sup> Smartseal 100P demonstrated effective taste masking, releasing only 1.1% of the drug in simulated salivary fluid (SSF) within two minutes, significantly lower than the pure drug (29.5%, <i>p</i> < 0.05), Kollicoat<sup>®</sup> MAE 100-55 (2.8%, <i>p</i> < 0.05), and comparable to Eudragit<sup>®</sup> EPO (2.1%, <i>p</i> > 0.05). Solubility studies further confirmed that theophylline release from the lead formulations remained well below its reported bitter threshold, which could prevent taste perception and mitigate bitterness. In gastric fluid, complete drug release was achieved from Kollicoat<sup>®</sup> Smartseal 100P and Eudragit<sup>®</sup> EPO, while Kollicoat<sup>®</sup> MAE 100-55 exhibited limited release. Stability studies showed that the Kollicoat<sup>®</sup> Smartseal 100P formulation maintained its texture, taste-masking efficacy, and dissolution profile under accelerated conditions. <b>Conclusions:</b> The study demonstrates the novel exploration of Kollicoat<sup>®</sup> Smartseal 100P for HME application, and its effectiveness in achieving robust taste masking for theophylline, improving patient compliance, particularly in pediatric and geriatric populations.

PharmaceuticsVol. 17(4)
University of Mississippi (US), University of Ha'il (SA)
Openalex Percentile: Top 13%
Advanced Drug Delivery Systems
2.37
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.